Tigermed, a prominent provider of innovative clinical research solutions, has announced it has successfully raised $80.0 million in new funding from investors. This significant capital infusion marks a key milestone for the company as it continues to expand its global operations and service offerings within the biopharmaceutical and medical device sectors.
The company, listed under stock codes 300347.SZ and 3347.HK, specializes in delivering comprehensive clinical research solutions across the entire life cycle of biopharmaceutical and medical device products. Tigermed's services span from initial clinical development through to commercialization, with a commitment to guiding customers and patients through their development journey efficiently and cost-effectively.
Tigermed currently operates a vast worldwide network, encompassing more than 100 subsidiaries and 180 service locations. It employs over 10,000 professionals across 50 countries, including regions in Asia Pacific, Europe, North & South America, and Africa, underscoring its extensive international footprint and capability.
This newly secured investment capital is intended to fuel Tigermed's strategic growth initiatives. The company plans to utilize the funds to further expand its comprehensive service portfolio, enhance its global operational capabilities, and invest in technological advancements to better serve the evolving needs of the healthcare industry.
Looking ahead, Tigermed remains dedicated to its mission of building an integrated platform that enables boundless possibilities for the healthcare industry. The company is committed to embracing challenges to fulfill its promise of serving unmet patient needs and ultimately contributing to saving lives globally.
